medigraphic.com
SPANISH

Annals of Hepatology

Órgano Oficial de la Asociación Mexicana de Hepatología
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

A Rare BSEP Mutation Associated with a Mild Form of Progressive Familial Intrahepatic Cholestasis Type 2

Waisbourd-Zinman O, Surrey LF, Schwartz AE, Russo PA, Wen J
Full text How to cite this article

Language: English
References: 14
Page: 465-468
PDF size: 3274.61 Kb.


Key words:

Cholestasis, PFIC2, Progressive Familial Intrahepatic Cholestasis, ABCB11, BSEP.

ABSTRACT

Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2) is a rare cholestatic disorder diagnosed in infancy or childhood that can lead to severe hepatic fibrosis and liver failure. Mutations in the ABCB11 gene result in a deficiency of the bile salt export protein (BSEP) and accumulation of bile inside the hepatocytes. Hepatocellular carcinoma is another condition associated with severe forms of deletion mutations in the ABCB11 gene. Treatment options including ursodeoxycholic acid biliary diversion have mixed outcomes and some patients require liver transplantation. Here, we describe two siblings with an extremely mild form of PFIC2 inherited from heterozygous parents. The elder sibling had acute liver failure at the age of six months and both siblings had pruritus, cholestasis, coagulopathy and fat-soluble-vitamin deficiencies in infancy but have been asymptomatic past infancy. Genetic testing of the siblings revealed that each were compound heterozygotes for two missense mutations of the ABCB11 gene: p.C68Y and p.R832H. Medical treatment typical for PFIC2 has not been necessary for either patient. This is the first report of these variants following a mild course in two affected patients.


REFERENCES

  1. Alsalloom A. Hepatocellular Carcinoma in a Boy with Progressive familial Intrahepatic Cholestasis Type II: Challenging Identification: Case report. Int J Health Sci (Qassim) 2013; 7: 252-5.

  2. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30: 134-46. doi: 10.1055/s-0030-1253223.

  3. Arnell H, Bergdahl S, Papadogiannakis N, Nemeth A, Fischler B. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg 2008; 43: 1312-20. doi: 10.1016/j.jpedsurg.2007.10.055.

  4. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25: 519-23. doi: 10.1002/ hep.510250303.

  5. Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol 2014; 4: 25-36. doi: 10.1016/j.jceh.2013. 10.005.

  6. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27. doi: 10. 1056/nejm199810223391707.

  7. Evason K, Bove KE, Finegold MJ, Knisely AS, Rhee S, Rosenthal P, Miethke AG, et al. Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies. Am J Surg Pathol 2011; 35: 687-96. doi: 10.1097/ PAS.0b013e318212ec87.

  8. Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, Wanty C, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol 2010; 53: 170-8. doi: 10.1016/ j.jhep.2010.01.034.

  9. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzáles E, Stieger B, Bernard O, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010; 51: 1645-55. doi: 10.1002/hep.23539.

  10. 10. van der Woerd WL, van Mil SW, Stapelbroek JM, Klomp LW, van de Graaf SF, Houwen RH. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol 2010; 24: 541-53. doi: 10.1016/j.bpg.2010.07.010.

  11. http://evs.gs.washington.edu/EVS/. Available at: URL.

  12. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. doi: 10.1038/gim.2015.30.

  13. Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, Gu J, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 2015; 13: 369-376.e3. doi: 10.1016/j.cgh.2014. 07.054.

  14. Summerfield JA, Scott J, Berman M, Ghent C, Bloomer JR, Berk PD, Sherlock S. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut 1980; 21: 154-60.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Ann Hepatol. 2017;16